A Randomized Controlled Trial on the Effects of Electromyographic Biofeedback on Quality of Life and Bowel Symptoms in Elderly Women With Dyssynergic Defecation

Dyssynergic defecation is a usual cause of chronic constipation in elderly women, with a negative impact on health-related quality of life. The present randomized controlled trial aims to evaluate the effects of behavioral treatment through electromyographic biofeedback (EMG-BF) on quality of life a...

Full description

Bibliographic Details
Main Authors: Miguel A. Simón, Ana M. Bueno, Patricia Otero, Fernando L. Vázquez, Vanessa Blanco
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:International Journal of Environmental Research and Public Health
Subjects:
Online Access:https://www.mdpi.com/1660-4601/16/18/3247
Description
Summary:Dyssynergic defecation is a usual cause of chronic constipation in elderly women, with a negative impact on health-related quality of life. The present randomized controlled trial aims to evaluate the effects of behavioral treatment through electromyographic biofeedback (EMG-BF) on quality of life and bowel symptoms in elderly women with dyssynergic defecation. Twenty chronically constipated elderly women, due to dyssynergic defecation, were enrolled in the study. Outcome measures included weekly stool frequency, anismus index, severity of patient-reported chronic constipation symptoms (abdominal, rectal, and stool symptoms), and overall measure of quality of life. After 1 month of baseline, participants were randomly assigned to either EMG-BF group (<i>n</i> = 10) or control group (<i>n</i> = 10). Three months after treatment, female patients were once again assessed following the same procedure in baseline. One-way multivariate analysis of variance MANOVA revealed no significant differences between the groups before treatment in any of the measured dependent variables (Wilks’s λ = 0.74; F<sub>6,13</sub> = 0.77; <i>p</i> = 0.61). Likewise, univariate analysis showed no differences between the groups, either in terms of age (F<sub>1,18</sub> = 0.96; <i>p</i> = 0.34) or mean disease duration (F<sub>1,18</sub> = 2.99; <i>p</i> = 0.11). Three months after treatment, MANOVA revealed statistically significant differences between the groups (Wilks’s λ = 0.29; F<sub>6,13</sub> = 5.19; <i>p</i> &lt; 0.01). These differences were significant in all outcome measures. EMG-BF produces significant improvements in bowel symptoms and health-related quality of life of elderly women with dyssynergic defecation.
ISSN:1660-4601